http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021
-
Veracyte (VCYT) Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results
-
Veracyte (VCYT) to Acquire Decipher Biosciences
-
Veracyte to Acquire Decipher Biosciences
-
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results
-
Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference
-
Veracyte (VCYT), Bayer Announce Precision Oncology Collaboration in Thyroid Cancer
-
Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer
-
Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer
-
Veracyte (VCYT) Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System
-
Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System
-
Veracyte (VCYT) Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests
-
Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests
-
Veracyte (VCYT) Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson
-
Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson
-
Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020
-
Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
-
Veracyte (VCYT) Announces New General Manager Structure
-
Veracyte Announces New General Manager Structure to Advance Global Expansion
-
Prosigna Breast Cancer Assay Now Approved for Reimbursement in Germany
-
Veracyte Announces Third Quarter 2020 Financial Results
-
Veracyte (VCYT) Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance
-
Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance
-
Veracyte Announces Publication of Manuscript Describing Scientific Rigor Behind Next-Generation Percepta Genomic Sequencing Classifier
-
Veracyte (VCYT) Announces New Data Reinforcing Foundational Technology of Nasal Swab Test for Early Lung Cancer Detection Presented at CHEST
-
Veracyte Announces New Data Reinforcing Foundational Technology of Nasal Swab Test for Early Lung Cancer Detection Presented at CHEST Annual Meeting 2020
-
Veracyte Announces Two Presentations to Be Shared at CHEST Annual Meeting 2020
-
Veracyte to Release Third Quarter 2020 Financial Results on November 2, 2020
-
Veracyte (VCYT) Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services
-
Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services
-
Veracyte to Present at Two Investor Conferences
-
Veracyte Announces Promotion of Richard T. Kloos, M.D. To Executive Medical Director
-
Veracyte (VCYT) Announces Initiation of Consensus Study Exploring Medical Utility of Multiple Breast Cancer Genomic Tests
-
Veracyte Announces Initiation of Consensus Study Exploring Medical Utility of Multiple Breast Cancer Genomic Tests
-
Veracyte to Present at Upcoming Investor Conferences
-
Veracyte Named a San Francisco Bay Area “Top Workplace” for Seventh Consecutive Year
-
Veracyte Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases
-
Veracyte (VCYT) Announces Positive Clinical Utility Data for Percepta Classifier Published in CHEST
-
Veracyte Announces Positive Clinical Utility Data for Percepta Classifier Published in CHEST
-
Veracyte Announces Second Quarter 2020 Financial Results
-
Veracyte Announces Data Published in AJRCCM Showing That the Envisia Genomic Classifier Improves Physicians’ Ability to Diagnose IPF Without Surgery
-
Veracyte (VCYT), MAVIDx Announce Agreement for MAVIDx to Develop Ultra-High Volume COVID-19 Testing on the nCounter System
-
Veracyte and MAVIDx Announce Agreement for MAVIDx to Develop Ultra-High Volume COVID-19 Testing on the nCounter System
-
Veracyte Appoints Jens Holstein to Board of Directors and James (Jim) Erlinger as Executive Vice President, General Counsel and Secretary
-
Veracyte to Release Second Quarter 2020 Financial Results on July 30, 2020
-
Veracyte (VCYT) Announces Clinical Utility Study Published in CHEST Demonstrates Envisia Genomic Classifier's Ability to Improve IPF Diagnosis
-
Veracyte Announces Clinical Utility Study Published in CHEST Demonstrates Envisia Genomic Classifier’s Ability to Improve IPF Diagnosis
-
Veracyte Announces De Novo Classification Request to FDA for the nCounter Dx LymphMark Assay
-
Veracyte to Present at the William Blair 40th Annual Growth Stock Conference
-
Veracyte to Present at the Jefferies Virtual Healthcare Conference

